Paper · 39769486
Cell Membrane- and Extracellular Vesicle-Coated Chitosan Methacrylate-Tripolyphosphate Nanoparticles for RNA Delivery.
Liew WJM and 5 others. Int J Mol Sci, 2024. Cited by 5 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Cell Membrane- and Extracellular Vesicle-Coated Chitosan Methacrylate-Tripolyphosphate Nanoparticles for RNA Delivery. Papers, record 39769486. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39769486
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Cell Membrane- and Extracellular Vesicle-Coated Chitosan Methacrylate-Tripolyphosphate Nanoparticles for RNA Delivery.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Chitosan | Major topic |
| Extracellular Vesicles | Major topic |
| RNA, Small Interfering | Major topic |
| Nanoparticles | Major topic |
| Humans | |
| Methacrylates | |
| Cell Membrane | |
| SARS-CoV-2 | |
| COVID-19 | |
| Erythrocyte Membrane |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| SUG | NTU/MSE | PubMed | ||
| RG40/19 (S) | MOE singapore | PubMed |
Source PubMed
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References66
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 11,516,493 | On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. | J Control Release | 2001 | https://conductscience.org/library/papers/11516493 | PubMed |
| 2 | 25,836,593 | Exosomes as drug delivery vehicles for Parkinson's disease therapy. | J Control Release | 2015 | https://conductscience.org/library/papers/25836593 | PubMed |
| 3 | 31,412,631 | Size Dependency of Circulation and Biodistribution of Biomimetic Nanoparticles: Red Blood Cell Membrane-Coated Nanoparticles. | Cells | 2019 | https://conductscience.org/library/papers/31412631 | PubMed |
| 4 | 22,310,103 | The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. | Curr Opin Immunol | 2012 | https://conductscience.org/library/papers/22310103 | PubMed |
| 5 | 29,582,476 | Cell Membrane Coating Nanotechnology. | Adv Mater | 2018 | https://conductscience.org/library/papers/29582476 | PubMed |
| 6 | 28,272,874 | Microfluidic Electroporation-Facilitated Synthesis of Erythrocyte Membrane-Coated Magnetic Nanoparticles for Enhanced Imaging-Guided Cancer Therapy. | ACS Nano | 2017 | https://conductscience.org/library/papers/28272874 | PubMed |
| 7 | 9,743,122 | Gene transfer into muscle by electroporation in vivo. | Nat Biotechnol | 1998 | https://conductscience.org/library/papers/9743122 | PubMed |
| 8 | 12,645,951 | Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59. | Eur J Immunol | 2003 | https://conductscience.org/library/papers/12645951 | PubMed |
| 9 | 23,827,988 | Cell-derived vesicles as a bioplatform for the encapsulation of theranostic nanomaterials. | Nanoscale | 2013 | https://conductscience.org/library/papers/23827988 | PubMed |
| 10 | 26,068,222 | Stability, Intracellular Delivery, and Release of siRNA from Chitosan Nanoparticles Using Different Cross-Linkers. | PLoS One | 2015 | https://conductscience.org/library/papers/26068222 | PubMed |
1 to 10 of 66
See all 66 referencesCited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,953,944 | Harnessing chemokines and nanocarriers to reprogram the tumor microenvironment. | Drug Deliv | 2026 | https://conductscience.org/library/papers/42953944 | PubMed |
| 42,605,503 | Precisely Engineering Biomimetic Nanoparticles via Controlled Cell Membrane Coating. | Small | 2026 | https://conductscience.org/library/papers/42605503 | PubMed |
| 41,146,652 | Advances in Targeted Engineered Nanoparticle-Based Therapeutics for Respiratory Diseases: Current Insights and Future Perspectives. | Int J Nanomedicine | 2025 | https://conductscience.org/library/papers/41146652 | PubMed |
| 40,862,965 | Microfluidic Platforms for Ex Vivo and In Vivo Gene Therapy. | Biosensors (Basel) | 2025 | https://conductscience.org/library/papers/40862965 | PubMed |
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39769486
GET https://conductscience.org/api/papers/v1/39769486/references?page=2